
|Articles|March 3, 2020
Managed Care Considerations for Navigating Biosimilar and HER2-Directed Therapies for the Treatment of HER2-Positive Breast Cancer
https://www.pharmacytimes.org/on-demand/managed-care-considerations-for-navigating-biosimilar-and-her2-directed-therapies-for-the-treatment-of-her2-positive-breast-cancer
Advertisement
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
Timely Outpatient Follow-Up Reduces Hospital Readmissions
2
Medicaid Work Requirements Set to Leave Millions Without Insurance
3
Changing Tumor Classifications May Explain Rise in Early-Onset CRC
4
AMCP Nexus 2025: Advancing Health Policy and Patient Outcomes Together
5















































